Study of BHV-1300 in Graves' Disease

Recruiting now · Phase 1

Conditions studied: Graves Disease

In brief

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Key facts

Study ID

NCT06980649

Run by

Biohaven Therapeutics Ltd.

People needed

15

Starts

2025-08-21

Expected to finish

2027-09-01

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Site-103 — South Gate, California, United States (enrolling)
• Site-100 — Miami, Florida, United States (enrolling)
• Site-104 — Columbus, Georgia, United States (enrolling)
• Site-108 — Greenville, North Carolina, United States (enrolling)
• Site-110 — Canton, Ohio, United States (enrolling)
• Site-107 — Memphis, Tennessee, United States (enrolling)
• Site-109 — Dallas, Texas, United States (enrolling)
• Site-106 — Houston, Texas, United States (enrolling)
• Site-101 — Houston, Texas, United States (enrolling)
• Site-105 — Shavano Park, Texas, United States (enrolling)
• Site-004 — Fitzroy, Australia (enrolling)
• Site-011 — Herston, Australia (enrolling)
• Site-001 — Kotara, Australia (enrolling)
• Site-003 — Melbourne, Australia (enrolling)
• Site-010 — Oaklands Park, Australia (enrolling)
• Site-008 — Parkville, Australia (enrolling)
• Site-006 — St Leonards, Australia (enrolling)
• Site-002 — Torquay, Australia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.